Trial reportScientific reports2026
The effect of astaxanthin supplementation on inflammatory markers, lipid profile, and anthropometric indices in patients with heart failure: a randomized controlled trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic inflammation and dyslipidemia are common pathophysiological features of heart failure (HF). Astaxanthin, a potent marine-derived antioxidant, has shown anti-inflammatory and lipid-lowering properties. This study conducted to evaluate the effect of astaxanthin supplementation on inflammatory markers, lipid profile, and anthropometric indices in patients with heart failure. In this 8-week double-blind, placebo-controlled clinical trial, 80 patients with stage C/D heart failure and left ventricular ejection fraction (LVEF) < 50% were randomly assigned to receive 20 mg/day of astaxanthin or placebo. Serum levels of Tumor Necrosis Factor alpha (TNF-α), Monocyte Chemoattractant Protein 1(MCP-1), and high sensitivity C Reactive Protein (hs-CRP), lipid profile, and anthropometric indices were assessed at baseline and post-intervention. Astaxanthin administration resulted in a significant reduction in TNF-α levels (-3.19 vs. -1.26 pg/mL; p = 0.013) and MCP-1 concentrations (-2.47 vs. 6.48 pg/mL; p = 0.004) compared to placebo. Additionally, very low-density lipoprotein (VLDL) levels decreased significantly (p = 0.024), while a non-significant reduction in total cholesterol was observed after adjustment (p = 0.061). No significant changes were observed in other lipid parameters, hs-CRP, or anthropometric measurements. Eight-week supplementation with 20 mg/day astaxanthin may have beneficial effects on selected inflammatory markers and limited effects on lipid parameters in patients with HF. Its effects on anthropometric indices remain inconclusive.Trial registration: Iranian Registry of Clinical Trials IRCT20200429047235N3. Registered on 26 March 2024. http//irct.behdasht.gov.ir/trial/75913.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.